Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Puma Biotechnology, Inc.
ClinicalTrials.gov Identifier:
NCT01111825
First received: April 22, 2010
Last updated: October 5, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2016
  Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 5, 2016